Advertisement


Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life

2021 San Antonio Breast Cancer Symposium

Advertisement

Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).



Related Videos

Breast Cancer
Immunotherapy

Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy

Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (Abstract GS1-02 ).

Breast Cancer

Banu Arun, MD, on Fine-Tuning Risk Assessment and Risk Reduction in Breast Cancer

Banu Arun, MD, of The University of Texas MD Anderson Cancer Center, discusses a session she moderated that included discussion of how exercise and diet may reduce the risk of breast cancer, and emerging non-endocrine treatments that may help prevent the disease.

Breast Cancer

Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer. Dr. Gnant also talks about whether any correlative studies hint at patient subgroups that this regimen may benefit (Abstract GS1-07) .

Breast Cancer
Immunotherapy

Peter Schmid, MD, PhD, on Early-Stage Triple-Negative Breast Cancer: Neoadjuvant Treatment With Pembrolizumab and Chemotherapy

Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).

Breast Cancer

Ann H. Partridge, MD, MPH, on SABCS Meeting Highlights: Expert Perspective

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses what she considers to be the most notable presentations at the 2021 San Antonio Breast Cancer Symposium. They include the focus on early-stage disease, especially in the TEXT/SOFT, RxPonder, and KEYNOTE-522 trials, as well as abstracts from the Early Breast Cancer Trialists’ Collaborative Group; and new data and novel therapeutics in the advanced setting.

Advertisement

Advertisement



Advertisement